Research Analysts Issue Forecasts for IGM Biosciences, Inc.’s Q2 2025 Earnings (NASDAQ:IGMS)

IGM Biosciences, Inc. (NASDAQ:IGMS) – Analysts at Wedbush issued their Q2 2025 earnings estimates for IGM Biosciences in a note issued to investors on Tuesday, October 1st. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.38) per share for the quarter. Wedbush currently has a “Outperform” rating and a $22.00 price objective on the stock. The consensus estimate for IGM Biosciences’ current full-year earnings is ($3.13) per share. Wedbush also issued estimates for IGM Biosciences’ Q3 2025 earnings at ($0.40) EPS and Q4 2025 earnings at ($0.40) EPS.

IGM Biosciences (NASDAQ:IGMS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of $0.18 by ($0.97). The firm had revenue of $1.25 million for the quarter, compared to analyst estimates of $51.75 million. IGM Biosciences had a negative return on equity of 119.02% and a negative net margin of 7,571.35%.

IGMS has been the topic of a number of other reports. HC Wainwright dropped their target price on shares of IGM Biosciences from $12.00 to $11.00 and set a “neutral” rating on the stock in a research report on Thursday, September 5th. Guggenheim cut their target price on shares of IGM Biosciences from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday. Truist Financial lowered IGM Biosciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $24.00 to $12.00 in a report on Tuesday. JPMorgan Chase & Co. downgraded IGM Biosciences from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $12.00 to $9.00 in a research note on Tuesday. Finally, Royal Bank of Canada lowered their price objective on shares of IGM Biosciences from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $14.67.

IGM Biosciences Stock Performance

NASDAQ:IGMS opened at $14.50 on Wednesday. IGM Biosciences has a 1 year low of $3.81 and a 1 year high of $22.50. The stock has a market cap of $855.85 million, a P/E ratio of -3.36 and a beta of 0.19. The stock has a 50-day simple moving average of $11.65 and a 200-day simple moving average of $9.75.

Institutional Trading of IGM Biosciences

A number of large investors have recently made changes to their positions in IGMS. Baker BROS. Advisors LP grew its holdings in shares of IGM Biosciences by 10.8% during the first quarter. Baker BROS. Advisors LP now owns 4,088,322 shares of the company’s stock worth $39,452,000 after buying an additional 397,311 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of IGM Biosciences by 19.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,888,023 shares of the company’s stock valued at $37,520,000 after purchasing an additional 628,001 shares during the period. Redmile Group LLC increased its stake in IGM Biosciences by 3.4% in the first quarter. Redmile Group LLC now owns 3,072,478 shares of the company’s stock valued at $29,649,000 after purchasing an additional 100,936 shares during the last quarter. TD Asset Management Inc lifted its position in IGM Biosciences by 3.4% during the second quarter. TD Asset Management Inc now owns 164,472 shares of the company’s stock worth $1,130,000 after buying an additional 5,350 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of IGM Biosciences by 126.0% during the 2nd quarter. Renaissance Technologies LLC now owns 108,693 shares of the company’s stock worth $747,000 after acquiring an additional 60,593 shares during the period. Institutional investors and hedge funds own 42.79% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Fred Schwarzer sold 3,946 shares of IGM Biosciences stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $11.54, for a total transaction of $45,536.84. Following the completion of the sale, the chief executive officer now directly owns 250,124 shares in the company, valued at approximately $2,886,430.96. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other IGM Biosciences news, CEO Fred Schwarzer sold 3,946 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $11.54, for a total value of $45,536.84. Following the sale, the chief executive officer now owns 250,124 shares of the company’s stock, valued at $2,886,430.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julie Hambleton sold 15,132 shares of IGM Biosciences stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $14.00, for a total transaction of $211,848.00. Following the transaction, the director now owns 2,000 shares of the company’s stock, valued at approximately $28,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,034 shares of company stock worth $279,957. 57.00% of the stock is owned by company insiders.

IGM Biosciences Company Profile

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.